V1RD15 Activators
Chemical activators of V1RD15 can induce its activation through various intracellular signaling pathways. Isoproterenol, Forskolin, PGE2, Histamine, and Adenosine share a common mechanism of increasing intracellular cyclic adenosine monophosphate (cAMP) levels, albeit through different receptors and enzymes. Isoproterenol, a beta-adrenergic agonist, and Histamine, through H2 receptors, activate Gs proteins that stimulate adenylyl cyclase, increasing cAMP production. Forskolin bypasses receptor engagement and directly activates adenylyl cyclase. PGE2 operates via its EP receptors, and Adenosine acts through A2A or A2B receptors, both also coupled to Gs proteins. The rise in cAMP from these activators leads to the activation of protein kinase A (PKA), which can phosphorylate and activate V1RD15.
Conversely, Vardenafil and Nitric Oxide donors initiate a cascade involving cyclic guanosine monophosphate (cGMP). Vardenafil inhibits phosphodiesterase type 5, preventing cGMP breakdown, while Nitric Oxide donors stimulate guanylyl cyclase to produce cGMP. Elevated levels of cGMP activate protein kinase G (PKG), which can phosphorylate V1RD15. IBMX, on the other hand, maintains increased levels of both cAMP and cGMP by inhibiting their degradation, leading to the activation of both PKA and PKG, with either capable of targeting V1RD15. In parallel, Anisomycin activates stress-activated protein kinases, including c-Jun N-terminal kinase (JNK), which can also lead to the phosphorylation of V1RD15. Bradykinin and Angiotensin II, via B2 and AT1 receptors respectively, engage Gq proteins to activate phospholipase C. This results in the production of diacylglycerol (DAG) and inositol trisphosphate (IP3), culminating in the activation of protein kinase C (PKC) which can then target V1RD15 for activation. Lastly, Epinephrine, through beta-adrenergic receptors, increases cAMP, activating PKA, which again is capable of phosphorylating V1RD15. Each of these chemical activators, through their distinct molecular interactions, result in the modulation and activation of V1RD15 via phosphorylation events facilitated by different kinases.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, through its action as a beta-adrenergic agonist, increases intracellular cAMP levels by activating adenylyl cyclase. This rise in cAMP can lead to the activation of protein kinase A (PKA), which then phosphorylates and activates various proteins, including V1RD15, as part of the downstream signaling cascade. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its G protein-coupled EP receptors, which can activate adenylyl cyclase and increase cAMP levels. The subsequent activation of PKA can lead to the phosphorylation and activation of V1RD15. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, when it binds to H2 receptors, activates adenylyl cyclase via Gs proteins, resulting in increased cAMP and activation of PKA. This activation cascade can result in the phosphorylation and functional activation of V1RD15. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with A2A or A2B receptors, which are coupled to Gs proteins that stimulate adenylyl cyclase, increasing cAMP levels. This rise in cAMP can activate PKA, leading to the phosphorylation and activation of V1RD15. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, a phosphodiesterase type 5 inhibitor, prevents the breakdown of cGMP, thereby sustaining its signaling. Elevated cGMP levels can activate PKG, which may phosphorylate and activate V1RD15 within cells responsive to cGMP-dependent signaling. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $43.00 $85.00 $158.00 | 7 | |
Nitric oxide donors, such as sodium nitroprusside, release nitric oxide which can activate guanylyl cyclase. The increased production of cGMP activates PKG, which, in turn, could phosphorylate and activate V1RD15. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-selective inhibitor of phosphodiesterases, leading to increased levels of both cAMP and cGMP by preventing their degradation. The resulting activation of PKA and PKG can lead to the phosphorylation and subsequent activation of V1RD15. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is an activator of the stress-activated protein kinases, which can lead to the activation of c-Jun N-terminal kinase (JNK). JNK activation can result in the phosphorylation of proteins within its signaling pathway, potentially including the activation of V1RD15 through downstream effects. | ||||||
Bradykinin | 58-82-2 | sc-507311 | 5 mg | $110.00 | ||
Bradykinin activates its B2 receptor, which can couple to Gq proteins and activate phospholipase C. This results in the production of IP3 and DAG, leading to increased intracellular calcium and the activation of protein kinase C (PKC). PKC, through its phosphorylation targets, might activate V1RD15 through downstream signaling events. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $51.00 $100.00 $310.00 $690.00 | 3 | |
Angiotensin II engages AT1 receptors, which can activate phospholipase C via Gq proteins, leading to the generation of IP3 and DAG. This increases intracellular calcium and activates PKC, which might lead to the phosphorylation and functional activation of V1RD15 as part of its downstream signaling effects. | ||||||